EGFR and non-small cell lung carcinoma: Although a few previous similar meta-analyses analyzed the benefits and disadvantages of first-line treatment for EGFR-mutated advanced NSCLC through indirect comparisons, there were still a large number of important RCTs whose results had not yet been published and therefore, required immediate updating [10,11].